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Abstract 
This paper presents the case of a previously well 72 year old man who spent 86 days 
in the intensive care unit (ICU) following a remarkable and explosive presentation of 
the rare condition thrombotic thrombocytopaenic purpura (TTP). TTP is an 
intravascular platelet aggregation disorder that, without treatment, is associated with 
significantly high mortality rates. This paper discusses TTP interms of its 
presentation, pathophysiology, diagnosis and management. In addition to TTP, the 
patient developed a number of comorbidities during his stay in ICU. Particular 
attention is given to two major problems: acute renal failure and prolonged 
encephalopathy. These issues, along with the initial diagnosis of TTP, resulted in the 
patient remaining in ICU for a longer period than otherwise might have been 
expected. Despite many obstacles, the patient recovered and was discharged from 
hospital 116 days after initial presentation. 
 
INTRODUCTION 
A 72 year old man (Mr N) presented to the emergency department 
of a private hospital in metropolitan Brisbane at approximately 
1000 hours after waking during the night with confusion and 
expressive dysphasia, which initially appeared to improve. Apart 
from a recent 3 week history of left shoulder pain on abduction, and 
previous history of excision of melanoma and multiple basal cell 
carcinomas, mild gastro-oesophageal reflux and appendicectomy, 
prior medical history was unremarkable. He was a non-smoker, did 
not take alcohol, used no regular medication, and there were no 
known drug allergies. 
 
On examination, he was unable to follow simple commands, and 
could not write his name or short sentences. Expressive dysphasia 
persisted. The cranial nerves were intact, and there was a good gag 
reflex. All limbs moved equally, with normal power. Even though he 
was dysphasic, Glasgow Coma Scale (GCS) score appeared to be 15. 
Computerised tomography (CT) brain scan was normal. Carotid 
duplex ultrasound revealed no significant carotid or vertebral artery 
disease. 12-lead electrocardiograph (ECG) was normal. Blood 
pressure was 150/90mmHg. Chest auscultation revealed dual heart 
sounds and clear air entry. Chest x-ray was normal. The abdomen 
was soft and he was afebrile. Laboratory findings are presented in 
Table 1. He was admitted with a provisional diagnosis of transient 
ischaemic attack (TIA). 
 
In the ward, he developed vomiting, and became less responsive 
and febrile. He was still quite dysphasic when alerted. GCS at 
1600 hours was 15; by 2000 hours this had deteriorated to 11. 
 
There were no other localising neurological signs. Tentative 
diagnoses now included herpes simplex encephalitis, or middle 
cerebral artery infarction. Urgent brain magnetic resonance 
imaging (MRI) was normal. It was thought that he had sepsis and 
dehydration superimposed on a minor stroke. Urinary tract 
infection was thought to be the most likely source, but biliary sepsis 
was also considered. He was treated with intravenous 
metoclopramide and fluids, and rectal paracetamol. An indwelling 
urinary catheter (IDC) was inserted, which drained concentrated 
and possibly bloody urine. Gentamicin was given prior to the 
collection of urine specimen and blood cultures. Fluid resuscitation 
was initiated with Albumex 4% and crystalloid. Intravenous 
ceftriaxone was commenced. 
 
Overnight, he became increasingly agitated, refused oral intake and 
pulled out his intravenous cannula. Intramuscular haloperidol 5mg 
was administered with no effect. On examination, he moved all 
limbs, with normal power. Pupils were equal and reactive to light. 
He opened his eyes to voice, but did not obey commands, and there 
was no vocalisation. Urine was dark and scant, with an estimated 
output of 150ml in 5 hours. There were apnoeic episodes lasting 
10-20 seconds. He had received 2.5mg of intravenous midazolam 
at the time of MRI, so intravenous naloxone 400mcg was trialled 
but predictably had no effect on apnoeas. 
 
Agitation became progressively worse, and further doses of 
parenteral haloperidol and midazolam were administered. There 
was no further urine output, but frank blood was present in the IDC 
tubing. Blood tests revealed advancing systemic disease. Table 1 
illustrates the rapid deterioration in Mr N’s condition. He was 
transferred to the intensive care unit (ICU) at 1230 hours on Day 2, 
some 24 hours after presentation, and was diagnosed with classic 
thrombotic thrombocytopaenic purpura (TTP). 
 
 
 
 
 
 
Table 1. Laboratory findings during the first 48 hours. 
 
 
 
 
THROMBOTIC THROMBOCYTOPAENIC PURPURA 
 
TTP was originally described in 1924 by Dr Eli Moschcowitz 1. It is 
a rare, classic disease of haematology 2, and is the most dangerous 
intravascular platelet aggregation disorder 3. Moschcowitz 
suspected a “powerful poison which had both agglutinative and 
haemolytic properties” 1 as the cause of this frightening new disease 4. 
TTP is a multi-system disorder, characterised by disseminated 
platelet aggregation with resultant thrombi formation in the 
microcirculation, leading to end-organ damage due to thrombotic 
ischaemia 1, 5, 6. The microvascular ‘hyaline’ thrombi occlude 
capillaries and arterioles, most commonly in the brain and kidneys 
(accounting for the dominant clinical features of the disease), but 
also in the heart, spleen, skin, endocrine glands (adrenals, 
pituitary), pancreas, eyes, skeletal muscles, ovaries, uterus, testes, 
gall bladder and lungs 3, 4, 7, 8. Venules are normally not involved 9. 
 
Allowing for the expected reaction to necrotic tissue, the 
inflammatory reaction to the thrombi is remarkably bland 10. The 
incomplete vascular occlusions, focal nature of the lesions, and lack 
of involvement of the venous channels permit sufficient collateral 
circulation to minimise parenchymatous damage; hence the 
potential for reversibility of the dysfunction of involved organs 10. Historically, TTP 
has been associated with a mortality rate of at least 90% 11. Even as late as 1965, 
most patients diagnosed with TTP died 12. With therapeutic plasma exchange, TTP 
has becomea curable illness 2, although it remains enigmatic from the 
perspective of its aetiology, pathophysiology and treatment 13. 
 
 
Clinical manifestations/diagnosis 
 
The presentation of TTP may be variable 8. A prodromal phase 
resembling a virus-like disease has been described in up to 40% of 
patients 14. Other presenting symptoms include weakness, malaise, 
fatigue, nausea and vomiting, pallor, jaundice and scleral icterus 5, 6, 
12, 14-16. Occasionally, the chief complaint may include the onset of 
pain at different locations such as joints and muscles (arthralgia and 
myalgia 7). Mr N complained of shoulder pain of three weeks’ 
duration prior to presentation. Muscular ache is caused by skeletal 
muscle ischaemia and myolysis 17. 
 
In over 90% of patients, purpura may be the initial manifestation 15, 
and is a consequence of the severe thrombocytopaenia 5. TTP is 
primarily a disorder of microcirculatory thrombosis, and severe or 
significant haemorrhage is rare 16, 18. However, purpura may be 
associated with gross haematuria 15, which has been a clinical 
feature in several studies 10, 14. Other manifestations include 
epistaxis, gingival haemorrhage, gastrointestinal bleeding 
(including melaena and haematemesis), menorrhagia, haemoptysis, 
and retinal, choroidal or vitreous haemorrhages 5, 7, 14. Petechial 
haemorrhages in the skin and ecchymoses are the most frequent 
forms of bleeding manifestations 7, 14. Generalised bruising/purpura 
was noted when Mr N was admitted to ICU. Patients can also 
suffer from visual defects because of microvascular ischaemia in the retinal 
circulation 16. Severe abdominal pain as a major presenting 
symptom is prominent in many series 12, 14. Abdominal pain 
presumably reflects bowel ischaemia due to microvascular 
obstruction 19. Abdominal pain may also be caused by TTPassociated 
pancreatitis 20. 
 
In classic cases, patients present with a pentad of clinical and 
laboratory findings: 
• Microangiopathic haemolytic anaemia (MAHA); 
• Thrombocytopaenia; 
• Neurologic symptoms and signs; 
• Renal function abnormalities; and 
• Fever 14. 
 
MAHA and thrombocytopaenia are the laboratory hallmarks 21. 
The anaemia that develops in TTP is a haemolytic type that is 
mechanical in origin 16. As red cells traverse high shear areas of 
microcirculation that are partially occluded by aggregating 
platelets, erythrocyte fragments are produced 4. This striking 
morphological feature of the peripheral blood (i.e. fragmentation) 
provides the most help in making the diagnosis of TTP 16. 
 
Detection of fragmented red blood cells (schistocytes) with the 
typical aspect of burr or helmet cells – together with a negative 
Coombs’ test (thus excluding immunologic destruction of 
erythrocytes) – are needed to confirm the microangiopathic nature 
of the haemolysis 4, 7, 11, 21. 
 
Thrombocytopaenia is usually severe, with platelet counts below 
20x109/L in most cases 3, 16. The degree of thrombocytopaenia 
reflects the extent of intravascular platelet clumping 4. 
Intravascular platelet aggregation also results in reduced platelet 
survival time 5. Thrombocytopaenia may be the earliest laboratory 
finding, preceding the full-blown syndrome 17. Mr N was 
thrombocytopaenic at presentation; other haematological values 
were still essentially normal at that time. 
 
TTP in its classic presentation is that of an acute change in mental 
status or neurologic function 22. Headache, altered state of 
consciousness, including somnolence, confusion and stupor, 
behavioural changes, syncope, vertigo, ataxia, visual symptoms, 
cranial nerve palsies, stroke, aphasia, dysarthria, slurred speech, 
paraesthesia, paresis, and focal or generalised seizures may be the 
presenting manifestation, or develop in the course of the disease 15, 17. 
Alteration in the state of consciousness may progress abruptly to 
coma 17. The initial neurologic manifestations are often transient 
and fluctuating; this rapid ‘waxing and waning’ of neurologic 
symptoms may be diagnostic for TTP 14. 
 
These bizarre symptoms are in keeping with transient occlusion of 
the cerebral microcirculation by platelet aggregates 17. There is an 
‘opening up’ of collateral circulation, and the persistence of some 
patent vessels to a given area of brain 23. Mr N’s presentation was 
consistent with this pattern, in that his dysphasia initially appeared 
to improve. Despite widespread vascular occlusions in the brain 
and severe neurologic manifestations, extensive infarction is 
unusual, and CT brain scan is often normal 7, 14, 17. Fever, if present, 
is usually low-grade 6, and is presumably due to hypothalamic 
ischaemia and/or tissue necrosis 17. 
 
It is to be expected that the kidney, as the most vascular organ in 
the body, should be involved in a disease process in which the 
major pathologic feature was recognised from the outset as widespread microvascular 
thrombi 10. The presence of some degree 
of renal involvement as an essential component in most cases of TTP 
is well-established 14. Renal abnormalities are present in 50-90% of 
episodes 10, 24, 25. However, renal insufficiency is usually mild 15. 
 
Abnormalities such as microscopic haematuria, and proteinuria 
with casts, are an almost constant feature 10, 15, 17. Oliguria and acute 
renal failure are uncommon 12, and dialysis is usually not required 26. 
Early diagnosis is important for two reasons: 
• Mortality in untreated patients may be as high as 80-90% 2, 3 It 
is possible that the true mortality is underestimated as the 
majority of deaths occur within 48 hours after presentation 11. 
• TTP has an excellent prognosis after adequate treatment 27. 
 
Before the era of effective treatment, TTP was diagnosed by the 
defining classic pentad of symptoms and physical 
findings 14. Diagnosis is frequently difficult, however, because the 
pentad is often incomplete at initial presentation 2, 3, 11. The danger 
is that by the time all five criteria are fulfilled, severe end-organ 
ischaemia has developed 16. Therefore, to avoid a potentially 
harmful delay in treatment, the diagnosis of TTP is frequently 
invoked when thrombocytopaenia and MAHA alone are present, 
in the absence of another likely cause 13. However, some patients 
may not be anaemic at the outset 2, although anaemia may progress 
rapidly following diagnosis and treatment 28 (Table 1). Similarly, 
red cell fragmentation may not appear until a day or two following 
clinical presentation 4. 
 
In Mr N’s case, spherocytes, fragmented cells and burr cells did not 
appear until Day 2, more than 24 hours after admission. 
Thrombocytopaenia and MAHA are obviously non-specific 
criteria 29 and, as a result, the diagnostic margins of this syndrome 
are inevitably indistinct 28. Thrombocytopaenia and haemolysis, as 
well as renal failure, are all common abnormalities in critically ill 
patients and often the aetiology is not clear. Therefore, TTP must 
be considered 28. Table 2 is a summary of important conditions that 
may mimic TTP. 
 
Other diagnostic considerations 
 
Haptoglobin is a glycoprotein that is synthesised in the liver. 
When red cells are destroyed in the vascular compartment, the 
haemoglobin escaping into plasma is bound to haptoglobin 30. In 
haemolytic anaemias characterised by intravascular haemolysis, 
catabolism of haptoglobin is so rapid that it basically disappears 
from the plasma31. Mr N’s haptoglobin on Day 2 was <0.06g/L (range 
0.25-1.80g/L). Evidence of intense haemolysis is also indicated by 
reticulocytosis (an index of accelerated erythropoiesis 32), which is 
increased to a degree appropriate for the severity of the anaemia 33. 
Reticulocyte count on Day 2 was normal, but polychromasia (a sign 
of red cell immaturity 34) was noted on Day 4. Leukocytosis is often 
present but is generally less than 20,000 cells/mm3 15. 
 
Because haemolysis is of the intravascular type, haemoglobinuria is 
usually present 33. Free haemoglobin was present in Mr N’s urine on 
Day 3. Hyperbilirubinaemia (mainly unconjugated) is an additional 
specific indicator of the accelerated red cell disruption 21. Serum 
lactate dehydrogenase (LDH) is almost invariably increased 17 due 
to the release of red blood cell LDH as a consequence of 
intravascular haemolysis, as well as systemic microvascular 
compromise35. Cohen et al. 35 found that 90% of patients manifested 
significant elevation in isoenzyme LDH5, which is derived from 
skeletal muscle and liver. Mr N’s total creatine kinase (CK) on 
presentation was 99U/L (range <200U/L). By Day 2 this had risen 
dramatically to 4098 U/L. 
 
Despite widespread platelet agglutination, TTP is not a primary 
disorder of coagulation or thrombin activation, so coagulation 
studies such as the activated partial thromboplastin time (APTT) 
and prothrombin time (PT) are characteristically normal 16 or only 
mildly disturbed 7, which helps to differentiate this condition from 
disseminated intravascular coagulation (DIC) 9. Fibrinogen levels 
are usually normal 9, 16. Mildly elevated fibrinogen degradation 
products (FDPs) have been reported 7. Table 3 summarises the 
characteristic laboratory abnormalities of TTP. 
Aetiology 
 
Precise figures relating to the incidence of TTP are elusive. The 
incidence in the United States may vary from one case per million 
people to one in 6,000 12, 36. The incidence in Australia is unclear, 
but only 13 different adults have been treated at the Mater Hospital 
apheresis unit in the past 5 years 37. TTP usually occurs in 
previously healthy people 33, and may occur in all age groups 14. It is 
more frequent in women, with a female to male ratio of 3:2 12, 14. 
Many clinical events regarded as possible precipitating factors for 
the disease have been reported. Multiple drugs have been causally 
implicated, including mitomycin, cyclosporine, tacrolimus and 
quinine 16, ticlodipine 38 and alcohol 39. There have been reported 
associations with countless bacterial and viral infections 40, 
including human immunodeficiency virus (HIV) 41; connective 
tissue diseases such as systemic lupus erythematosus (SLE) 16; as well 
as pregnancy, malignancy, bone marrow transplantation and total 
body irradiation 16. Genetic and environmental influences 42, 43 have 
also been proposed. Other more obscure associations include bee 
sting 44, dog bite 45 and carbon monoxide poisoning 46. However, the 
majority of cases are truly idiopathic 6, and most patients have a 
single acute episode that never recurs after successful therapy 5. 
 
Pathophysiology 
 
The hypotheses concerning the pathophysiology of TTP are 
controversial, and suggest different pathogenetic mechanisms being 
responsible for development of the disorder 5. Several lines of 
evidence suggest that von Willebrand factor (vWF) is involved 26: 
• TTP thrombi contain, in addition to platelets, an abundance of 
vWF, but little or no fibrinogen/fibrin 47. 
• vWF is present on the surface of platelets in patients with TTP 4. 
• Unusually large vWF multimers (ULvWF) are present in TTP 
plasma 48. 
 
The entire constellation of vWF multimers found in the normal 
circulation is produced within both megakaryocytes and endothelial 
cells, and is stored within the α-granules of platelets and the 
Weibel-Palade bodies of endothelial cells 4. Megakaryocytes and 
endothelial cells also construct ULvWF, which are not a normal 
constituent of circulating plasma 4. The presence of ULvWF in 
TTP plasma may reflect the failure of the plasma to process 
adequately the ULvWF released from endothelial cells 4. 
 
It has been found that TTP is associated with a severe deficiency of 
a vWF-cleaving metalloproteinase 49. In the absence of this 
proteinase, vWF is not cleaved to smaller forms 50. The uncleaved, 
ULvWF may be more effective at binding under the influence of 
elevated fluid shear stresses (such as that encountered in arterioles 
and capillaries 39) to platelet receptors and complexes, resulting inmetalloproteinase 
activity has been detected in many of the 
patients studied in detail 50. 
 
Interestingly, it has been found that some individuals with 
congenital proteinase deficiency have never had an acute TTP 
event 39. This indicates that a deficiency of vWF-cleaving 
proteinase alone may not be sufficient to cause acute TTP 39. Many 
authorities believe that microvascular endothelial dysfunction or 
injury is an important step in the sequence of events leading to 
disease manifestation 5, 39. Some kind of trigger (drugs, bacteria, 
pregnancy etc.) leads to activation or death of the microvascular 
endothelial cells 39. Endothelial damage is known to result in the 
release of high molecular weight forms of vWF from the Weibel- 
Palade bodies and their appearance in the regional circulation 51. 
 
The majority of patients have a quantitative elevation of vWF 24, 
which supports the generally accepted concept that TTP is 
ultimately related to some form of endothelial cell damage or 
stimulation 52. In Mr N’s case, vWF:Ag levels were raised on Day 2, 
at 1.79U/ml (range 0.5-1.6U/ml). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2. Differential diagnosis of TTP. 
 
 
 
 
Table 3. Characteristic laboratory abnormalities of TTP 16. 
 
Management 
 
In view of Mr N’s extreme agitation on arrival in ICU, he was 
intubated and mechanically ventilated in order to facilitate 
insertion of a subclavian central venous line, radial arterial line and 
femoral vascath, in anticipation of commencing plasma exchange. 
The femoral site is generally the first choice, as haemostasis may be 
assisted by local compression as needed 18. All puncture sites 
immediately began to ooze. There was also fresh blood oozing 
around the IDC, with blood and clots draining from within the 
IDC, requiring continuous bladder irrigation. Frusemide infusion 
was commenced at 30mg/hour, in view of deteriorating renal 
function. Plasma exchange was commenced at approximately 1900 
hours on Day 2. 
 
There is probably no other disease in which prompt diagnosis and 
treatment can lead to as great a difference in clinical outcome as with 
adult TTP18. The accepted standard of care for TTP, and indeed, the 
critical element of treatment, is daily plasma exchange 2, 13, i.e. the 
combination of plasmapheresis and plasma infusion with normal 
platelet-poor fresh frozen plasma (FFP) 4. Acute TTP can be treated 
successfully by intensive plasma manipulation in nearly 90% of 
patients 24, 25. A delay in initiating plasma exchange may result in 
treatment failure 18. 
 
Plasma exchange requires a large-diameter, dual-lumen central 
venous catheter, similar to that required for haemodialysis (HD). 
The patient’s blood is withdrawn, and the plasma is mechanically 
separated from cells by centrifugation. The patient’s cells are then 
returned with fresh, therapeutic donor plasma 53. It is presumed that 
harmful substances such as ULvWF and autoantibodies against 
vWF-cleaving metalloproteinase are removed by plasmapheresis 4, 
and that the infusion of normal plasma provides supplemental 
quantities of the vWF-cleaving metalloproteinase that is inhibited 
by autoantibodies 49, 50. Studies on serial plasma samples show that 
plasma proteinase activity rises after patients are treated with 
plasma therapy 50. 
 
Usually, one plasma volume equivalent to 40ml/kg of body weight 
is exchanged per session 21. Mr N’s regime involved volume 
exchanges of 1.0, 1.5 and 2.0 plasma volumes; the majority were 
double plasma volume exchanges. There are no clinical data to 
support a frequency of plasma exchange exceeding once per day 11, 
nor do there appear to be any scientific studies that have precisely 
determined the optimal treatment schedule. Some patients recover 
after one plasma exchange28, while others require prolonged therapy 9. 
In one case, 145 exchanges over 221 days were required 28. The 
median number of treatments is about 15 over 3 weeks 28. Mr N 
required 21 exchanges over a period of 31 days to achieve a 
remission (one session was aborted after an hour because of a 
massive upper gastrointestinal bleed). 
 
If a delay in institution of plasma exchange is unavoidable for 
technical reasons, or if it is unavailable, as in a distant rural site, it 
is appropriate to initiate therapy with plasma infusion and 
glucocorticoids 29. However, plasma infusion should not be viewed 
as an acceptable alternative to plasma exchange for anything but a 
short-term measure 18. A randomised controlled trial comparing 
plasma infusion with plasma exchange definitively confirmed the 
superiority of the latter 24. The infusion of FFP alone may be 
associated with an increased rate of relapse 25, as well as the risk of 
volume overload, which is increased by renal insufficiency 4. 
Until relatively recently, established practice was to use FFP as the 
replacement fluid in plasma exchange 54. To optimise themanagement of TTP, 
alternatives to FFP have been sought 11. 
 
Cryoprecipitate-poor plasma (CPP), or cryosupernatant, is one 
such option 11. CPP is the residual plasma fraction after the 
separation of cryoprecipitate, and is mostly depleted of vWF, 
fibrinogen, fibronectin and factor XIII 18, 21. CPP is a logical option 
because it lacks ULvWF multimers, which have been implicated in 
the pathophysiology of TTP 11, while at the same time retaining 
vWF-cleaving proteinase activity 4. The superiority of CPP over 
FFP in terms of improved response rates and lower mortality has 
been demonstrated54. The replacement fluid used for Mr N’s plasma 
exchange consisted of 100% CPP, or CPP in combination with FFP. 
4% albumin was introduced as a partial exchange fluid at the ninth 
exchange on Day 10 because of a persistent metabolic alkalosis. 
Plasmapheresis commonly induces metabolic alkalosis in TTP 
patients, probably due to the high citrate content of FFP 55. 
Encouraging findings have been reported with a combination of 5% 
albumin and plasma (CPP/FFP), in terms of response time and 
mortality rate 13, but the potential benefits of albumin as partial 
replacement require further study 13. 
 
Response to plasma exchange/ therapeutic targets 
 
The response to plasma exchange may be variable, perhaps 
reflecting the heterogeneity of TTP syndromes 2. An initial 
response may occur within minutes of beginning the first exchange, 
or may not be observed for over 1 month 25. Thrombocytopaenia 
typically requires several days for initial recovery to begin 2, 53. Large 
day-to-day fluctuations in the platelet count are common, 
particularly when plasma therapy is instituted 7. Mr N’s platelet count 
dropped to 23x109/L on Day 3, remained below 50 until Day 6, and 
did not exceed 100 until Day 10. Platelet count did not normalise 
(160) until Day 28. 
 
A recent survey of 20 institutions in the United States confirmed 
the wide variability of therapeutic targets 13. However, serum LDH 
and platelet count generally appear to be the most important 
parameters on which treatment decisions are based 2, 21. A platelet 
count of at least 150x109/L appears to be a requirement for 
discontinuation of daily plasma exchange 13, but others accept 
platelet counts of 100 or 200 13. However, on completion of the first 
cycle of plasma exchange on Day 17, Mr N’s platelet count was just 
38x109/L. Whereas treatment decisions based on platelet count 
appear to be widely popular, measurement of serum haptoglobin is 
rarely mentioned in discussions of therapeutic targets. In Mr N’s 
case, haptoglobin level was regarded as an important indicator of 
clinical improvement or deterioration. Mr N commenced plasma 
exchange on Day 2, when haptoglobin was <0.06 g/L (range 0.25- 
1.80 g/L). On Day 17, haptoglobin was normal at 1.4g/L. On this 
basis, rather than the platelet count, plasma exchange was 
discontinued. 
 
Many patients have a prompt exacerbation of thrombocytopaenia 
and haemolysis when plasma exchange is tapered. In these 
patients, it is assumed that TTP has remained active and requires 
continued treatment for control 28. Mr N’s first treatment cycle 
consisted of 16 consecutive daily treatments. At approximately 29 
hours after completion of the first cycle, red cell count (RCC) had 
dropped from 3.17 to 2.63x1012/L, and haemoglobin from 91 to 
77g/L. By Day 23, haptoglobin had dropped to 0.3g/L, although 
platelets had improved somewhat to 61x109/L. He received further 
plasma exchange on Days 24 and 25. By Day 29, haptoglobin had 
again dropped to <0.06g/L. Platelets had improved to 192x109/Lbut RCC was still 
only 2.77x1012/L, and haemoglobin 78g/L. 
 
Additional plasma exchange was performed on Days 29, 31 and, 
finally, on Day 32. At that time, platelets were 313x109/L, 
haemoglobin 100g/L, RCC 3.41x1012/L and haptoglobin (on Day 
30) 0.2g/L. On Day 35, three days after the last plasma exchange, 
haptoglobin was normal at 1.3g/L, and remained so thereafter. 
As with platelets, similar variability has been seen with LDH 
therapeutic targets 13. Some institutions require LDH to be within 
their normal reference ranges prior to discontinuing daily plasma 
exchange, while others discontinue treatment as long as LDH is 
approaching the patient’s baseline (near normal). Some centres do 
not follow LDH in their management of TTP 13. LDH may improve 
promptly 2 and become normal before recovery of the platelet 
count, or may remain slightly elevated for several weeks 28. Mr N’s 
LDH normalised on Day 15, but had risen again by Day 22. On the 
final day of plasma exchange (Day 32), LDH remained high at 415 
U/L, and essentially remained elevated until Day 100. However, 
there were many contributory factors in this setting. 
 
Schistocytes in declining numbers often persist for many days on 
peripheral blood films, and so cannot be used as a reliable marker of 
remission 4. Occasional fragmented red cells were still present on 
film on Day 87. Anaemia may continue to worsen and further red 
cell transfusion is often required 2, based on the critical 
haemoglobin level and degree of haemolysis 16, and also if the 
patient has symptoms of shock or insufficient tissue oxygenation 22. 
Mr N received many transfusions of packed cells (at least 78 units), 
but normal values for both RCC and haemoglobin were never 
achieved during his hospitalisation. 
Ancillary therapies 
 
In the past, the widespread platelet aggregation observed in TTPhas led to the use of 
platelet inhibitor drugs (PID), including 
aspirin, dipyridamole, sulfinpyrazone and dextran 8. PID have been 
associated with haemorrhagic complications in severely 
thrombocytopaenic patients 24, 25. Therefore, they cannot currently 
be recommended for patients with TTP who have profound 
thrombocytopaenia 16. On the other hand, given the proposed 
autoimmune pathogenesis (i.e. the demonstration of 
autoantibodies abolishing vWF-cleaving proteinase activity in 
many cases 4), a strong rationale for steroid use now exists 49, 50. 
 
Glucocorticoids may suppress the production of autoantibodies 
against the vWF-cleaving metalloproteinase 3. Because of the 
efficacy of plasma exchange, assessing the additional benefit of 
ancillary therapies such as glucocorticoids has been difficult 16. 
However, it is prudent to institute glucocorticoid therapy – in 
association with plasma exchange – in all adult patients with initial 
TTP episodes, unless there is a strong contraindication 4. The 
recommended dosage is 200mg/day of intravenous prednisolone 3. 
Mr N was commenced on methylprednisolone on Day 2, at a dose 
of 100mg twice daily. The dose was reduced to 100mg daily on Day 
13 and ceased on Day 14. 
 
Platelet transfusion 
 
Patients with TTP have experienced abrupt, striking deterioration 
after platelet transfusion 25. Generally, platelets should not be 
transfused because they are thought to increase clumping and 
worsen the associated microvascular disease 56. There have been 
reports of fatalities 56. If the platelet count is very low and bleeding 
is severe or life-threatening (such as intracranial bleeding) 4, 21, 27, 
transfusion of platelets at a slow rate (to minimise the risk of 
microvascular occlusion 3) will be necessary 4. Platelet infusion may 
also be required before invasive procedures 21. Packed red blood 
cells, on the other hand, are depleted of platelets and can be given 
safely 18. 
 
Mr N received several units of platelets following a massive upper 
gastrointestinal haemorrhage, and prior to percutaneous 
tracheostomy (this procedure was abandoned following major 
haemorrhage into the trachea on wire insertion). Further platelets 
were given prior to surgical tracheostomy. Administration of 
platelets in these instances did not appear to intensify the disease 
process. 
 
Encephalopathy 
 
Although neurological symptoms usually dominate the clinical 
picture in TTP 21, and may worsen in the initial days after diagnosis 24, 
they are often reversible with expeditious treatment 16. Non-focal 
neurologic symptoms, such as mental status changes, may resolve 
immediately and dramatically 2, 53, or may subside within 48 hours 
after initiation of plasma therapy 2. The observation that many 
comatose patients with TTP become alert during plasmapheresis 
and plasma exchange establishes that this is effective therapy 25. 
TTP patients have also recovered from prolonged comas without 
neurological sequelae after receiving intensive plasma exchange 57. 
Therefore, even if a patient is comatose and does not respond to 
initial treatment, repeated plasma exchange and other supportive 
therapies should be maintained 9. 
 
Mr N’s neurological status became an issue of serious concern 
during his stay in ICU. He became encephalopathic during the 
early days of his illness, and this persisted for a significant period of 
time. The prolonged encephalopathy was variably attributed to 
TTP with small cerebral vessel disease (even though 
encephalopathy persisted long after TTP was deemed quiescent), 
steroids, critical illness, cytokines, and metabolic and drug factors. 
He became extremely agitated whenever sedation was lightened, 
with head thrashing and continuous non-specific limb activity. 
Nursing him was very difficult, in terms of maintaining integrity of 
the endotracheal tube/tracheostomy, ventilator/humidifier circuit, 
and invasive lines. It was also distressing for Mr N’s family to see 
him in this condition. A number of sedation regimes were 
implemented, including various combinations of fentanyl, 
midazolam, propofol, methadone, haloperidol and diazepam. 
 
Sedation was complicated by marked hypotension, even with small 
boluses of sedatives. Noradrenaline was required for a period. CT 
brain scans on Days 11 and 36 were normal. Encephalopathy was 
a persistent feature. Mr N did not obey commands until Day 51, at 
which time he was sedated solely with propofol. Neurological 
status improved (albeit extremely slowly) from this point, with 
boluses of midazolam and propofol as required to allow trouble-free 
operation of dialysis equipment. 
 
Renal failure 
 
Haemoglobinuria and hyperbilirubinaemia may have nephrotoxic 
effects in the presence of extracellular volume depletion 10. Given 
the critical state in which some of these patients present, a 
compromise in the extracellular fluid volume is a common problem. 
Fluid replacement should be an early and integral part of the 
supportive therapy of every patient with TTP 10. 
 
While plasma exchange obviously has a dramatic effect on the 
course of TTP, the renal prognosis of patients so treated remains 
unclear 58. Plasma exchange typically reduces the need for HD 18, 
but a minority of patients require urgent HD 8, and its use to achieve 
rapid volume control and correction of uraemia occupies an 
important role in the management of such patients 10. A higher 
serum creatinine at presentation may be associated with the 
eventual need for HD 58. Continuous renal replacement therapy                                 
(CRRT), using a PRISMA 
CFM TM machine, was commenced on Day 5 for a creatinine of 
0.551mmol/L and urea of 38.0mmol/L. Urine output was 
frusemide-driven. There was also an element of fluid overload, 
with a conservatively estimated positive fluid balance of 3.6L. In 
order to limit the number of vascular access devices, with their 
attendant risks (in particular, the potential for bleeding 
complications), it was preferable to use the same device for both 
plasma exchange and CRRT. The logistics of this were often 
complicated, but nursing staff quickly settled into a routine whereby 
Mr N was dialysed immediately following completion of daily 
plasma exchange. Continuous veno-venous haemodiafiltration 
(CVVHDF) was the mode of choice. Gambro haemofiltration 
solution (formula no. 1) was used. 
 
Mr N received approximately 704 hours of CRRT over a period of 
45 days. Blood flow of 120-180ml/minute was used, according to 
his haemodynamic status. He was generally able to tolerate a blood 
flow of 180ml/minute. Filtration and dialysate rates of 1000- 
2000ml/hour were used. Fluid was removed at a rate of 0- 
500ml/hour, according to fluid balance and haemodynamic 
parameters. CRRT was discontinued on several occasions to 
observe the effect on renal parameters, but renal function remained 
dialysis-dependent until CRRT was finally ceased on Day 58. 
Renal failure in TTP patients may worsen before improvement is 
noted 2, and it often resolves more slowly than other parameters 18. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4. Summary of Mr N’s co-morbidities 
during 86 days in ICU. 
 
 
 
Many patients who develop renal failure requiring dialysis 
subsequently recover renal function 58, although it may take several 
months, and may be incomplete in many cases 53. However, a 
persistent azotaemia does not necessarily indicate failure of therapy 18, 
and the development of chronic renal failure is uncommon 14, 15. A 
mild renal impairment persisted until Mr N was discharged from 
hospital. 
 
Mr N was ready for transfer to the ward on Day 72. He remained 
mildly confused. Other issues that emerged during his stay in ICU 
are summarised in Table 4. Unfortunately, he was readmitted to 
ICU on Day 78 with nausea, vomiting, abdominal pain and a rising 
white cell count (WCC). Laparotomy revealed gross peritonitis, a 
possibly perforated jejunal diverticulum and gangrenous acalculous 
cholecystitis. Small bowel resection and cholecystectomy were 
performed. There followed another period of mechanical 
ventilation. Wound closure was delayed until Day 81, and he was 
extubated on Day 85. Mini-tracheostomy was required for sputum 
clearance. Multiresistant Acinetobacter calcoaceticus was identified 
in intra-abdominal and peri-tracheal specimens, as well as in 
sputum. Mr N was transferred to the ward on Day 92, and was 
discharged from hospital on Day 116. 
 
CONCLUSION 
 
TTP is a rare, potentially life-threatening disease of haematology. 
Patients may present with a diverse array of symptoms; however, 
renal and neurologic manifestations are prevalent. MAHA and 
thrombocytopaenia are essential diagnostic considerations. The 
aetiology and pathophysiologic mechanisms of TTP remain 
uncertain and debated. vWF is likely to be involved, as is a 
deficiency of a vWF-cleaving metalloproteinase. 
 
The accepted standard of care for TTP is daily therapeutic plasma 
exchange. CPP is the preferred replacement fluid. Additional 
therapies include administration of glucocorticoids. Red cell 
transfusion is often required, but platelet transfusion has been 
associated with adverse outcomes. Therapeutic targets may vary 
between institutions. Critically ill patients such as Mr N require 
intensive supportive care, not only in terms of managing TTP, but 
also from the perspective of treating coexisting illnesses or the 
complications that inevitably arise during a prolonged stay in ICU 
(TTP patients with severe renal and neurologic impairment often 
have a more protracted clinical course before remission is achieved 
59). TTP is a frightening, complicated and perplexing disease. Early 
diagnosis and treatment are absolutely essential if a positive 
outcome is to be achieved. 
 
Postscript 
 
This was a most severe case of TTP, and medical and nursing staff 
were often dismayed by Mr N’s apparent lack of progress. At times 
the outlook appeared bleak, with limited new treatment options, 
other than time and patience. Mr N’s wife and family visited daily, 
and the strain associated with this, especially for his slightly frail 
wife, was obvious. However, there is no doubt that the unwavering 
support provided by Mr N’s family played a significant role in his 
recovery. Mr N and his wife visited the ICU 3 weeks after his 
discharge from hospital. There was no sign of TTP, and only very 
modest renal impairment. He had regained full independence with 
mobility and other activities of daily living, and was generally 
making an outstanding recovery from the multitude of problems 
that plagued him during his stay in ICU 
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